Approach to the Sensitized Patient Awaiting Heart Transplantation

被引：0

作者：

Patel J.K. ^{[1
]}

Kobashigawa J.A. ^{[1
]}

机构：

[1] Advanced Health Sciences Pavilion, Cedars-Sinai Heart Institute, 8700 Beverly Blvd, Los Angeles, 90054, CA

来源：

Current Transplantation Reports | 2014年 / 1卷 / 4期

关键词：

Antibodies; Desensitization; Heart transplant;

D O I：

10.1007/s40472-014-0031-8

中图分类号：

学科分类号：

摘要：

The management of the sensitized patient awaiting heart transplant remains a challenge and an active area of research. The development of solid-phase immunoassays (including the C1q assay) has allowed high-resolution determination of antibodies most likely to be associated with antibody-mediated rejection and adverse outcomes. The precision of these techniques has permitted the adoption of the virtual crossmatch, substantially expanding the donor pool for sensitized patients and reducing wait times to transplant. Desensitization strategies continue to evolve, and the most effective therapies appear to be a combined approach utilizing antibody depletion, targeted B cell or plasma cell therapy, or immunomodulation. Further therapy in addition to cytolytic induction may be required at transplant, with judicious monitoring post-transplant for antibody rebound and rejection. © 2014, Springer International Publishing AG.

引用

页码：290 / 299

页数：9

共 52 条

[1]

Terasaki P.I., Humoral theory of transplantation, Am J Trans: off J Am Soc Trans Am Soc Trans Surg, 3, 6, pp. 665-673, (2003)

[2]

Lavee J., Kormos R.L., Duquesnoy R.J., Zerbe T.R., Armitage J.M., Vanek M., Et al., Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation, J Heart Lung Trans: Off Publ Int Soc Heart Trans, 10, 6, pp. 921-929, (1991)

[3]

Kobashigawa J.A., Sabad A., Drinkwater D., Cogert G.A., Moriguchi J.D., Kawata N., Et al., Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?, Circulation, 94, pp. II294-II297, (1996)

[4]

Nwakanma L.U., Williams J.A., Weiss E.S., Russell S.D., Baumgartner W.A., Conte J.V., Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era, Ann Thorac Surg, 84, 5, pp. 1556-1562, (2007)

[5]

Densmore T.L., Goodnough L.T., Ali S., Dynis M., Chaplin H., Prevalence of HLA sensitization in female apheresis donors, Transfusion, 39, 1, pp. 103-106, (1999)

[6]

Tait B.D., Dandie W.J., Griffiths A.P., Esmore D.S., Snell G.I., Bergin P., Et al., Covert presensitization to HLA antigens in parous heart and lung transplant recipients may predispose to early allograft rejection, Transplant Proc, 27, 3, pp. 2143-2144, (1995)

[7]

Stringham J.C., Bull D.A., Fuller T.C., Kfoury A.G., Taylor D.O., Renlund D.G., Et al., Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization, J Heart Lung Trans: Off Publ Int Soc Heart Trans, 18, 2, pp. 160-165, (1999)

[8]

Drakos S.G., Kfoury A.G., Kotter J.R., Reid B.B., Clayson S.E., Selzman C.H., Et al., Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization, J Heart Lung Trans: Off Publ Int Soc Heart Trans, 28, 8, pp. 838-842, (2009)

[9]

George I., Colley P., Russo M.J., Martens T.P., Burke E., Oz M.C., Et al., Association of device surface and biomaterials with immunologic sensitization after mechanical support, J Thorac Cardiovasc Surg, 135, 6, pp. 1372-1379, (2008)

[10]

Shankar N., Daly R., Geske J., Kushwaha S.K., Timmons M., Joyce L., Et al., LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay, Transplantation, 96, 3, pp. 324-330, (2013)

← 1 2 3 4 5 6 →